Published March 26, 2018
| Version v1
Journal article
Open
Development of a viability assay for the HSJD-DIPG-007 cell line
- 1. Structural Genomics Consortium, Oxford
Description
Development and optimisation of a CellTiter-Glo based viability assay of the HSJD-DIPG-007 cell line for use in later drug screening efforts. An initial dataset including screening data of two ALK2 inhibitors shown to be active against this cell line is included.
Notes
Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Files
Developing_a_DIPG_cell_line_viability_assay_180320.pdf
Files
(1.5 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:8872959dabb59646742811a322d54784
|
596.5 kB | Preview Download |
|
md5:7f409b06573bddfa5c58923a73bb33e9
|
878.9 kB | Download |